[ASAP] Discovery of N-Aryl-N′-[4-(aryloxy)cyclohexyl]squaramide-Based Inhibitors of LXR/SREBP-1c Signaling Pathway Ameliorating Steatotic Liver Disease: Navigating the Role of SIRT6 Activation 🔗 Access full article via ACS Journal of Medicinal ChemistryShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
